Imagine being so dumb as to pin your hopes on this Conflict of Interest Disclosures: Dr Liau reported serving on the board of directors of ClearPoint Neuro outside the submitted work and having a patent pending for combinations of inhibitors with dendric cell vaccines to treat cancer. Dr Ashkan reported receiving grants from Northwest Biotherapeutics during the conduct of the study. Dr Brem reported receiving travel support from Northwest Biotherapeutics outside the submitted work. Dr Campian reported receiving grants from NeoImmue Tech and support for investigator-initiated clinical trials from Incyte, Merck, and Ipsen outside the submitted work. Dr Iwamoto reported receiving grants from Northwest Biotherapeutics and serving on the steering committee of this trial during the conduct of the study and receiving personal fees from AbbVie, Alexion, Gennao Bio, Novocure, Kiyatec, Medtronic, Merck, Guidepoint, Mimivax, Massive Bio, Tocagen, Regeneron, and Xcures outside the submitted work. Dr Tran reported receiving grants from Novocure, Moteris, Lacerta, Sarepta, Merck, Novartis, Northwest Biotherapeutics, Stemline, Celldex, Orbus, TVax, and Tocagen; receiving travel support from Novartis; and serving on the advisory board of Novocure during the conduct of the study. Dr Goldlust reported receiving institutional support from Northwest Biotherapeutics during the conduct of the study; receiving consulting fees from Boston Biomedical, Sumitomo Danippon Pharma, Cornerstone Specialty Network, Cellevolve, Daiichi Sankyo, and Novocure; serving on the speakers’ bureau for Novocure and Physicians Education Resources; receiving food and drink from Novocure; and owning stock in COTA outside the submitted work. Dr Grewal reported receiving personal fees from AstraZeneca, Vivacitas Oncology, and xCures; receiving sample medication from AbbVie/Allergan; and being the founder of Genomet outside the submitted work. Dr Avigan reported serving on the advisory boards of Bristol Myer Squibb, Chugai, Merck, Kite, and Legend; receiving grants from Sanofi, and serving as a consultant for Parexel outside the submitted work. Dr Fink reported receiving funding from Northwest Biotherapeutics during the conduct of the study and receiving funding from Novocure, Denovo Biopharma, Stemline, CNS Pharmaceuticals, Servier Pharmaceuticals/Agios, and Sumitoma Pharma outside the submitted work. Dr Giglio reported receiving study support from the Medical University of South Carolina during the conduct of the study; receiving grants from Denovo Biopharma, Novocure, BioMimetix, Celgene, EORTC, the Canadian Cancer Trials Group, Institut de Recherches Internationales Servier, the Global Coalition for Adapative Research, and Prelude outside the submitted work; and having a patent pending for the epitranscriptomic analysis of glioma. Dr Lutzky reported receiving grants from Bristol Myer Squibb and serving on the advisory boards of Iovance and Castle outside the submitted work. Dr Meisel reported receiving personal fees from BG Klinikum Bergmannstrost during the conduct of the study and receiving consulting fees paid to Regenerate Life Sciences from Stayble Therapeutics and royalties from Fehling Instruments outside the submitted work. Dr Sanchin reported receiving personal fees from BG Klinikum Bergmannstrost during the conduct of the study. Dr Dunbar reported receiving speaking fees from GT Medical during the conduct of the study. Dr Pluward reported receiving grants from Northwest Biotherapeutics during the conduct of the study. Dr Mulholland reported receiving support to attend a conference from Northwest Biotherapeutics during the conduct of the study. Dr Pearlman reported receiving compensation for serving as a site principal investigator from Northwest Biotherapeutics during the conduct of the study. Dr Prins reported having patent UCLA Case No. 2015-341 pending. Drs Boynton and Bosch reported being employees of and owning shares in Northwest Biotherapeutics, Inc. Dr Boynton reported having a patent held by Northwest Biotherapeutics. Dr Bosch reporting having patent 13/492693 pending. jamanetwork.com/journals/jam…

This week in Frisco, we sat down over dinner with a small group of CISOs and senior security leaders for a focused conversation on AI risk. The premise was simple. Most organizations now have an AI policy. Far fewer have a clear view of where AI is actually creating risk inside the business. The conversation kept returning to one idea. AI is no longer an experiment running at the edges. It is inside core business processes, often without clear oversight, and the exposure it creates is not theoretical. It is legal, financial, and reputational. Patrick Zeller and Keith Weisman framed where that exposure actually lives: → Where AI is introducing risk inside the business today → Why AI deserves to be treated as the new insider threat → Why security leaders need to bring legal and risk teams in before an issue surfaces, not after These questions are landing on the CISO's desk faster than most teams have guidance to answer them. Thank you, GuidePoint Security, for co-hosting and bringing the right room together. When AI is already in your business processes, who owns the risk? #aigovernance #ciso #airisk

OK smarty pants, here is the "conflicts of interest" section of the 2022 DCVax JAMA piece. It's almost as long as the total report!!!! LOL. 🤣🤣🤣 Talk about CONFLICTS!!!!!?????? You got scammed dummy. Conflict of Interest Disclosures: Dr Liau reported serving on the board of directors of ClearPoint Neuro outside the submitted work and having a patent pending for combinations of inhibitors with dendric cell vaccines to treat cancer. Dr Ashkan reported receiving grants from Northwest Biotherapeutics during the conduct of the study. Dr Brem reported receiving travel support from Northwest Biotherapeutics outside the submitted work. Dr Campian reported receiving grants from NeoImmue Tech and support for investigator-initiated clinical trials from Incyte, Merck, and Ipsen outside the submitted work. Dr Iwamoto reported receiving grants from Northwest Biotherapeutics and serving on the steering committee of this trial during the conduct of the study and receiving personal fees from AbbVie, Alexion, Gennao Bio, Novocure, Kiyatec, Medtronic, Merck, Guidepoint, Mimivax, Massive Bio, Tocagen, Regeneron, and Xcures outside the submitted work. Dr Tran reported receiving grants from Novocure, Moteris, Lacerta, Sarepta, Merck, Novartis, Northwest Biotherapeutics, Stemline, Celldex, Orbus, TVax, and Tocagen; receiving travel support from Novartis; and serving on the advisory board of Novocure during the conduct of the study. Dr Goldlust reported receiving institutional support from Northwest Biotherapeutics during the conduct of the study; receiving consulting fees from Boston Biomedical, Sumitomo Danippon Pharma, Cornerstone Specialty Network, Cellevolve, Daiichi Sankyo, and Novocure; serving on the speakers’ bureau for Novocure and Physicians Education Resources; receiving food and drink from Novocure; and owning stock in COTA outside the submitted work. Dr Grewal reported receiving personal fees from AstraZeneca, Vivacitas Oncology, and xCures; receiving sample medication from AbbVie/Allergan; and being the founder of Genomet outside the submitted work. Dr Avigan reported serving on the advisory boards of Bristol Myer Squibb, Chugai, Merck, Kite, and Legend; receiving grants from Sanofi, and serving as a consultant for Parexel outside the submitted work. Dr Fink reported receiving funding from Northwest Biotherapeutics during the conduct of the study and receiving funding from Novocure, Denovo Biopharma, Stemline, CNS Pharmaceuticals, Servier Pharmaceuticals/Agios, and Sumitoma Pharma outside the submitted work. Dr Giglio reported receiving study support from the Medical University of South Carolina during the conduct of the study; receiving grants from Denovo Biopharma, Novocure, BioMimetix, Celgene, EORTC, the Canadian Cancer Trials Group, Institut de Recherches Internationales Servier, the Global Coalition for Adapative Research, and Prelude outside the submitted work; and having a patent pending for the epitranscriptomic analysis of glioma. Dr Lutzky reported receiving grants from Bristol Myer Squibb and serving on the advisory boards of Iovance and Castle outside the submitted work. Dr Meisel reported receiving personal fees from BG Klinikum Bergmannstrost during the conduct of the study and receiving consulting fees paid to Regenerate Life Sciences from Stayble Therapeutics and royalties from Fehling Instruments outside the submitted work. Dr Sanchin reported receiving personal fees from BG Klinikum Bergmannstrost during the conduct of the study. Dr Dunbar reported receiving speaking fees from GT Medical during the conduct of the study. Dr Pluward reported receiving grants from Northwest Biotherapeutics during the conduct of the study. Dr Mulholland reported receiving support to attend a conference from Northwest Biotherapeutics during the conduct of the study. Dr Pearlman reported receiving compensation for serving as a site principal investigator from Northwest Biotherapeutics during the conduct of the study. Dr Prins reported having patent UCLA Case No. 2015-341 pending. Drs Boynton and Bosch reported being employees of and owning shares in Northwest Biotherapeutics, Inc. Dr Boynton reported having a patent held by Northwest Biotherapeutics. Dr Bosch reporting having patent 13/492693 pending.

Guidepoint really needs a comments section on the public KOL calls.

Gen Z Is Redefining the Medical Aesthetics Patient Journey, New Guidepoint Qsight Study Finds financewire.com/2026/06/11/g…

Sporting clays with GuidePoint Security on Friday. Charles Connolly went on Reach's behalf. He says he hit a few. We believe him. Great company, quality conversations, no laptops. Thanks to GuidePoint for putting it together. #Cybersecurity #ReachSecurity

🚨 How XBOW & GuidePoint Are Revolutionizing Exploitable Risk Validation: A Technical Deep Dive Video undercodetesting.com/how-xbo… Educational Purposes!

Security outcomes improve when great technology is paired with trusted expertise. It was great spending time with the @GuidePointSec team and customers at the GuidePoint Security Golf Classic at Terry Hills yesterday. As organizations face a growing volume of vulnerabilities and increasingly complex attack surfaces, partnerships matter. Together, we're helping organizations move beyond finding vulnerabilities to continuously validating real, exploitable risk.

There's still time! Don't miss the chance to unwind with the cybersecurity community and connect with our Zscaler Delivery Certified Experts at GuidePoint Security's #ZenithLive Happy Hour: okt.to/aNGjHu

Most healthcare software tracks what happened. GuidePoint guides staff through what happens next. Real-time clinical decision flows for sterile processing departments. No more tribal knowledge.

➤ Stream the latest episode of the Car Dealership Guy Podcast now on your favorite platform—brought to you by GuidePoint Systems Youtube: carguymedia.com/4dSXzM5 Apple Podcasts: carguymedia.com/4u9KHpy Spotify: carguymedia.com/4eiTfFO

Diagnostic data is becoming part of the fixed ops trust equation. Karen Chagnon, VP of Sales at GuidePoint Systems, explains how vehicle alerts can help dealers reassure customers when a warning light turns on.

➤ Stream the latest episode of the Car Dealership Guy Podcast now on your favorite platform—brought to you by GuidePoint Systems Youtube: carguymedia.com/4dSXzM5 Apple Podcasts: carguymedia.com/4u9KHpy Spotify: carguymedia.com/4eiTfFO

Service outreach is getting more precise in fixed ops. Karen Chagnon, VP of Sales at GuidePoint Systems, explains how real vehicle data is helping dealers reach customers before the service visit is overdue.

The Guidepoint MCP is now available in Perplexity Computer, allowing Guidepoint customers to integrate 100,000 expert interview transcripts into their finance AI workflows, with traceable citations back to the original transcript.

GLG / guidepoint have good lists, but have found from personal experience cold emailing / calling is just as effective. Benefit of using an expert network is that you can source a richer sampling of prospective candidates

Guidepoint lanza MCP en Claude insurgentepress.com.mx/guide…

We're co-hosting the AI for Finance Summit New York with LinqAlpha on June 2, part of NY TECH WEEK by a16z. Alternative data has been discussed for years. Prediction markets are finally being taken seriously. And AI is changing what's possible in research and trading workflows, faster than most firms are ready for. That's what this forum is about. All sessions under Chatham House Rule. Confirmed speakers and attendees from J.P. Morgan, BlackRock, Coatue Management, Polymarket, XTX Markets, ICE, Google, and more. Huge thanks to AQR Capital Management and Guidepoint for their support in making this happen. This is invite-only with very limited capacity. We review every RSVP manually and keep the room small on purpose. 📅 June 2 | 4:30–7:00 PM ET | New York City Register below.

6/ 🔌 金融数据也接进来了。 Claude 连接 FactSet、Capital IQ、MSCI、PitchBook、Morningstar、LSEG、Daloopa 等数据源。 还新增 D&B、Fiscal AI、Guidepoint、IBISWorld、Third Bridge、Verisk 等连接器。

Our 2025 North America Partner of the Year is @GuidePointSec! 👏 A trusted advisor to some of the most security-conscious organizations, GuidePoint consistently brings deep expertise and a practical approach — helping customers cut through complexity and focus on what’s truly exploitable and worth fixing. Congratulations to the entire GuidePoint team for their hard work! #PartnerFirst #AISecurity #ProactiveSecurity